GlassScriptPhysician profile
Jose M Garmendia
NPI 1235173139
$2,882.54
in general payments reported to CMS, 2019-2025
32 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $316 · 2021: $588 · 2022: $288 · 2023: $572 · 2024: $456 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.04 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $337.53 | 2019-2024 | |
| Lilly USA, LLC | $266.81 | 2022-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $218.50 | 2022-2024 | Farxiga, Airsupra |
| Kyowa Kirin, INC. | $191.99 | 2019-2021 | |
| Corcept Therapeutics | $182.31 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.24 | 2019-2024 | Jardiance |
| Amgen INC. | $155.08 | 2019-2023 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $148.51 | 2019-2022 | |
| Astellas Pharma US INC | $126.50 | 2023-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $113.40 | 2019-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $108.81 | 2020-2022 | |
| Insmed, INC. | $101.12 | 2025 | Arikayce, Brinsupri |
| Bayer Healthcare Pharmaceuticals INC. | $85.87 | 2021-2025 | |
| Dexcom, INC. | $80.45 | 2021-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $77.78 | 2020-2023 | Eliquis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $74.98 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Neurocrine Biosciences, INC. | $51.75 | 2023 | Ongentys, Ingrezza |
| Abbvie INC. | $51.03 | 2020-2025 | |
| Mannkind Corporation | $46.79 | 2024 | |
| Pfizer INC. | $38.73 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $38.19 | 2023 | Quviviq |
| Almatica Pharma LLC | $29.69 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $25.67 | 2021 | |
| Medtronic Vascular, INC. | $23.96 | 2019 | |
| Abbott Laboratories | $23.01 | 2022 | |
| Abiomed | $21.77 | 2023 | Impella |
| Inspire Medical Systems, INC. | $21.44 | 2023 | Inspire |
| Biogen, INC. | $17.60 | 2020 | |
| Smith+Nephew, INC. | $15.77 | 2024 | Collagenase Santyl |
| Medtronic, INC. | $15.54 | 2024 | Minimed 780g |
| Allergan, INC. | $14.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Garmendia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.